Related Experiment Videos
[Oral gestagen treatment of advanced breast neoplasms with norethisterone acetate]
Abstract:
The medical records of 84 postmenopausal women treated with oral norethisterone acetate (NTA) for advanced breast cancer have been analyzed retrospectively. Treatment was devoid of significant toxicity. 21 patients were not evaluable for treatment response, either due to insufficient data or inadequate tratment trial. Among the 63 evaluable patients, complete plus partial response was obtained in 21 (33.3%) with a median duration of 10 months. Disease stabilization was observed in 16 patients (25.4%) for a median duration of 5 months, while 26 patients (41.3%) showed progressive disease while on treatment. The best response was observed in women with predominantly soft tissue metastases (CR + PR: 34.9%) and aged over 70 (CR + PR: 48%). The literature on norethisterone acetate is reviewed and compared with the present results. The role of progestational agents in the treatment of advanced mammary carcinoma is discussed.
Insights
Oral norethisterone acetate (NTA) showed a 33.3% response rate in postmenopausal women with advanced breast cancer. This progestational agent demonstrated low toxicity and potential efficacy, particularly in specific patient groups.
Area of Science:
- Oncology
- Pharmacology
Context:
- Advanced breast cancer treatment in postmenopausal women.
- Retrospective analysis of medical records.
Purpose:
- To evaluate the efficacy and toxicity of oral norethisterone acetate (NTA) in advanced breast cancer.
- To compare findings with existing literature on progestational agents.
Summary:
- Norethisterone acetate (NTA) was administered to 84 postmenopausal women with advanced breast cancer.
- Among 63 evaluable patients, 33.3% achieved complete or partial response (median duration 10 months), 25.4% had stable disease (median duration 5 months), and 41.3% progressed.
- Best responses were seen in patients with soft tissue metastases and those over 70 years old.
Impact:
- Norethisterone acetate (NTA) offers a low-toxicity treatment option for advanced breast cancer.
- Identifies patient subgroups (soft tissue metastases, >70 years) who may benefit most from NTA.
- Contributes to understanding the role of progestational agents in mammary carcinoma management.